Purification of melanoma reactive T cell by using a monocyte-based solid phase T-cell selection system for adoptive therapy

Journal of Immunotherapy

Volumn 31, Issue 1, 2008, Pages 81-88

  Li, Jongming ^a   Mookerjee, Bijoyesh ^a   Wagner, John ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Antigen specific T cells; Melan A; Melanoma; T cell selection

Indexed keywords

CELL ANTIGEN; HLA A ANTIGEN; MELAN A; TUMOR ANTIGEN; EPITOPE; GAMMA INTERFERON; HLA A*0201 ANTIGEN; HLA-A*0201 ANTIGEN; MART1 ANTIGEN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PURIFICATION; ARTICLE; CELL PROLIFERATION; CELL SELECTION; CELL STIMULATION; CELL SURFACE; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMOBILIZED CELL; MELANOMA; MONOCYTE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FOLDING; T LYMPHOCYTE; CELL COMMUNICATION; CELL SEPARATION; CULTURE TECHNIQUE; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY TEST; IMMUNOLOGY; METABOLISM; METHODOLOGY; MONONUCLEAR CELL; TUMOR CELL LINE;

ANTIGENS, NEOPLASM; CELL COMMUNICATION; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL SEPARATION; CYTOTOXICITY TESTS, IMMUNOLOGIC; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; HLA-A ANTIGENS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; LEUKOCYTES, MONONUCLEAR; MELANOMA; MONOCYTES; NEOPLASM PROTEINS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 40749145347     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318157c668     Document Type: Article

References (19)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
2. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850-854.
3. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following nonmyeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23:2346-2357.
4. Grakoui A, Bromley SK, Sumen C, et al. The immunological synapse: a molecular machine controlling T cell activation. Science. 1999;285:221-227.
5. Monks CR, Freiberg BA, Kupfer H, et al. Three-dimensional segregation of supramolecular activation clusters in T cells. Nature. 1998;395:82-86.
6. Lezzi G, Karjalainen K, Lanzavecchia A. The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity. 1998;8:89-95.
7. Valmori D, Fonteneau JF, Lizana CM, et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/ MART-1 immunodominant peptide analogues. J Immunol. 1998;160:1750-1758.
8. Dauer M, Obermaier B, Herten J, et al. Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J Immunol. 2003;170:4069-4076.
9. + T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J Immunol. 2003;171:2251-2261.
10. + T-cell clones for immunotherapy from the naive repertoire. J Immunol Methods. 2006;310:40-52.
11. Hensel N, Melenhorst JJ, Bradstock K, et al. Flow cytometric quantitation and characterization of the T-lymphocyte memory response to CMV in healthy donors. Cytotherapy. 2002;4:29-40.
12. Brunner KT, Mauel J, Cerottini JC, et al. Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology. 1968;14:181-196.
13. Cheever MA, Chen W. Therapy with cultured T cells: principles revisited. Immunol Rev. 1997;157:177-194.
14. Dudley ME, Wunderlich J, Nishimura MI, et al. Adoptive transfer of cloned melanoma reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother. 2001;24:363-373.
15. Dudley ME, Wunderlich JR, Yang JC, et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother. 2002;25:243-251.
16. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA. 2002;99:16168-16173.
17. Topalian SL, Muul LM, Solomon D, et al. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods. 1987;102:127-141.
18. Clay TM, Custer MC, McKee MD, et al. Changes in the fine specificity of gp100209-217-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue. J Immunol. 1999;162:1749-1755.
19. Yang S, Linette GP, Longerich S, et al. Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity. J Immunol. 2002;169:531-539.